Περίληψη:
Noninvasive biomarkers for early pancreatic ductal adenocarcinoma (PDAC) diagnosis and disease risk stratification are greatly needed. We conducted a nested case-control study within the Prospective Investigation into Cancer and Nutrition (EPIC) cohort to evaluate prediagnostic microRNAs (miRs) as biomarkers of subsequent PDAC risk. A panel of eight miRs (miR-10a, -10b, -21-3p, -21-5p, -30c, -106b, -155 and -212) based on previous evidence from our group was evaluated in 225 microscopically confirmed PDAC cases and 225 controls matched on center, sex, fasting status and age/date/time of blood collection. MiR levels in prediagnostic plasma samples were determined by quantitative RT-PCR. Logistic regression was used to model levels and PDAC risk, adjusting for covariates and to estimate area under the receiver operating characteristic curves (AUC). Plasma miR-10b, -21-5p, -30c and -106b levels were significantly higher in cases diagnosed within 2 years of blood collection compared to matched controls (all p-values <0.04). Based on adjusted logistic regression models, levels for six miRs (miR-10a, -10b, -21-5p, -30c, -155 and -212) overall, and for four miRs (-10a, -10b, -21-5p and -30c) at shorter follow-up time between blood collection and diagnosis (≤5 yr, ≤2 yr), were statistically significantly associated with risk. A score based on the panel showed a linear dose-response trend with risk (p-value = 0.0006). For shorter follow-up (≤5 yr), AUC for the score was 0.73, and for individual miRs ranged from 0.73 (miR-212) to 0.79 (miR-21-5p). © 2017 UICC
Συγγραφείς:
Duell, E.J.
Lujan-Barroso, L.
Sala, N.
Deitz McElyea, S.
Overvad, K.
Tjonneland, A.
Olsen, A.
Weiderpass, E.
Busund, L.-T.
Moi, L.
Muller, D.
Vineis, P.
Aune, D.
Matullo, G.
Naccarati, A.
Panico, S.
Tagliabue, G.
Tumino, R.
Palli, D.
Kaaks, R.
Katzke, V.A.
Boeing, H.
Bueno-de-Mesquita, H.B.
Peeters, P.H.
Trichopoulou, A.
Lagiou, P.
Kotanidou, A.
Travis, R.C.
Wareham, N.
Khaw, K.-T.
Ramon Quiros, J.
Rodríguez-Barranco, M.
Dorronsoro, M.
Chirlaque, M.-D.
Ardanaz, E.
Severi, G.
Boutron-Ruault, M.-C.
Rebours, V.
Brennan, P.
Gunter, M.
Scelo, G.
Cote, G.
Sherman, S.
Korc, M.
Λέξεις-κλειδιά:
biological marker; microRNA; microRNA 106b; microRNA 10a; microRNA 10b; microRNA 155; microRNA 21 3p; microRNA 21 5p; microRNA 212; microRNA 30c; unclassified drug; microRNA; tumor marker, adult; age distribution; aged; Article; blood sampling; cancer diagnosis; cancer risk; case control study; cohort analysis; controlled study; diet restriction; female; follow up; human; major clinical study; male; pancreas adenocarcinoma; pancreas adenoma; priority journal; prospective study; protein blood level; quantitative analysis; receiver operating characteristic; reverse transcription polymerase chain reaction; sex ratio; time factor; area under the curve; blood; genetics; middle aged; pancreas carcinoma; pancreas tumor; polymerase chain reaction; sensitivity and specificity, Adult; Aged; Area Under Curve; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Case-Control Studies; Female; Humans; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Polymerase Chain Reaction; Prospective Studies; ROC Curve; Sensitivity and Specificity
